Evidence map›Paper›PMID 36312950›Full record

ArticleFrontiers in microbiology2022

Strain level and comprehensive microbiome analysis in inflammatory bowel disease

Jayamary Divya Ravichandar, Erica Rutherford, Cheryl-Emiliane T Chow, Andrew Han, Mitsuko Lynn Yamamoto, Nicole Narayan, Gilaad G Kaplan, Paul L Beck, Marcus J Claesson, Karim Dabbagh and 2 more

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jayamary Divya RavichandarSecond Genome Inc., Brisbane, CA, United States.
Erica RutherfordSecond Genome Inc., Brisbane, CA, United States.
Cheryl-Emiliane T ChowSecond Genome Inc., Brisbane, CA, United States.
Andrew HanSecond Genome Inc., Brisbane, CA, United States.
Mitsuko Lynn YamamotoSecond Genome Inc., Brisbane, CA, United States.
Nicole NarayanSecond Genome Inc., Brisbane, CA, United States.
Gilaad G KaplanDepartment of Medicine, University of Calgary, Calgary, AB, Canada.
Paul L BeckDepartment of Medicine, University of Calgary, Calgary, AB, Canada.
Marcus J ClaessonSchool of Microbiology, University College Cork, Cork, Ireland.
Karim DabbaghSecond Genome Inc., Brisbane, CA, United States.
Shoko IwaiSecond Genome Inc., Brisbane, CA, United States.
Todd Z DeSantisSecond Genome Inc., Brisbane, CA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Inflammatory bowel disease (IBD) is a heterogenous disease in which the microbiome has been shown to play an important role. However, the precise homeostatic or pathological functions played by bacteria remain unclear. Most published studies report taxa-disease associations based on single-technology analysis of a single cohort, potentially biasing results to one clinical protocol, cohort, and molecular analysis technology. To begin to address this key question, precise identification of the bacteria implicated in IBD across cohorts is necessary. Methods: We sought to take advantage of the numerous and diverse studies characterizing the microbiome in IBD to develop a multi-technology meta-analysis (MTMA) as a platform for aggregation of independently generated datasets, irrespective of DNA-profiling technique, in order to uncover the consistent microbial modulators of disease. We report the largest strain-level survey of IBD, integrating microbiome profiles from 3,407 samples from 21 datasets spanning 15 cohorts, three of which are presented for the first time in the current study, characterized using three DNA-profiling technologies, mapping all nucleotide data against known, culturable strain reference data. Results: We identify several novel IBD associations with culturable strains that have so far remained elusive, including two genome-sequenced but uncharacterized Conclusion: We propose MTMA for uncovering experimentally testable strain-disease associations that, as demonstrated here, are beneficial in discovering mechanisms underpinning microbiome impact on disease or novel targets for therapeutic interventions.

Indexed as

16S rRNAgut microbiomeinflammatory bowel diseasemeta-analysismetagenomicsstrain

Identifiers

PMID36312950
PMCPMC9614153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.